



## Join us at ASCO!

### Lung Cancer- Metastatic

#### General Poster Session

**Date/Time: Saturday, May 30<sup>th</sup> from 2:00 PM – 6:00 PM**

Location: Level 2, West Hall C, Poster Board Q15

- #8089: Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer. Joseph M. Amann, PhD

### Clinical Science Symposium

#### Personalizing Treatment for Squamous Cell Carcinoma of the Head and Neck: How Do We Use New Molecular Prognostic and Predictive Factors in the Clinic?

**Date/Time: Monday, June 1<sup>st</sup> at 9:45 AM – 11:45 AM**

Location: Level 2, West Hall F3

Chair: Ezra E.W. Cohen, ME, FRCPC

- #6000: Mass spectrometry profile as a predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. C.H. Chung, MD